Lab Reference Library / Lipoprotein(a)
Inflammation & Cardiovascular
Lipoprotein(a)
Lp(a) · Lipoprotein Little a · Lp(a) ParticleReference range, optimal functional medicine levels, and why Lp(a) is the most underdiagnosed genetic cardiovascular risk factor, why most patients have never been tested, and why a single elevated Lp(a) result changes lifetime cardiovascular risk management strategy.
Cardiovascular RiskGenetic Risk Factor
Standard RangeBelow 75 nmol/L
Low RiskBelow 30 nmol/L
High RiskAbove 125 nmol/L
Unitsnmol/L
← Back to Lab Reference Library
Category: Inflammation & Cardiovascular | Also known as: Lp(a), Lipoprotein Little a, Lp(a) Particle | Sample: Serum or plasma; fasting not required; only needs to be measured once in most patients
1. What This Test Measures
Lipoprotein(a), universally abbreviated as Lp(a) and pronounced "lipoprotein little a," is a unique lipoprotein particle that has no parallel among the standard lipid panel measurements. Structurally, Lp(a) consists of an LDL-like core particle with apolipoprotein B-100 (ApoB) on its surface, to which an additional distinctive glycoprotein called apolipoprotein(a) (apo(a)) is covalently attached by a disulfide bond.
Three structural features of apo(a) define Lp(a)'s unique clinical significance:
- Structural similarity to plasminogen: apo(a) is encoded by the LPA gene and evolved from gene duplication of plasminogen, the precursor to plasmin (the primary fibrinolytic enzyme). Because Lp(a) mimics plasminogen structure, it competitively inhibits plasmin-mediated fibrinolysis, impairing the body's ability to break down blood clots and directly promoting thrombosis.
- Isoform size variability: apo(a) contains a variable number of kringle IV type 2 (KIV-2) repeats encoded by the LPA gene, ranging from approximately 2 to 40 repeats. Smaller apo(a) isoforms (fewer repeats) are associated with higher Lp(a) serum concentrations. Isoform size is genetically fixed and does not change with lifestyle or treatment.
- Proinflammatory and oxidized phospholipid transport: Lp(a) carries a disproportionate fraction of oxidized phospholipids (OxPL) in the circulation. OxPL are potent drivers of vascular inflammation and foam cell formation, contributing to atherosclerotic plaque progression beyond Lp(a)'s atherogenic cholesterol cargo.
Critically, serum Lp(a) concentration is 80 to 90% genetically determined, primarily by LPA gene variants, and is largely unresponsive to the dietary, exercise, and lifestyle modifications that effectively reduce LDL. This makes Lp(a) the most significant purely genetic cardiovascular risk factor currently identified, and the reason that identifying elevated Lp(a) requires a fundamentally different clinical management approach than identifying elevated LDL.
2. Why This Test Matters
- Most underdiagnosed genetic cardiovascular risk factor: approximately 20% of the population has Lp(a) above 125 nmol/L (the high-risk threshold), conferring cardiovascular risk equivalent to heterozygous familial hypercholesterolemia. Because Lp(a) is not included in standard lipid panels, most of these high-risk individuals have never been tested, are not aware of their risk, and are not receiving appropriate risk factor management.
- Independent risk multiplication: elevated Lp(a) is multiplicatively dangerous when combined with other cardiovascular risk factors. A patient with elevated LDL and elevated Lp(a) has dramatically higher risk than either factor alone. The combination of Lp(a) above 125 nmol/L with elevated ApoB is particularly associated with very early onset, aggressive cardiovascular disease.
- Aortic valve stenosis: elevated Lp(a) is strongly associated with calcific aortic valve stenosis, an increasingly recognized consequence of Lp(a)-mediated OxPL-driven valve calcification. This is an important and distinct cardiovascular consequence of elevated Lp(a) beyond coronary artery disease.
- Premature cardiovascular disease explanation: in patients with premature myocardial infarction (before age 55 in men, before age 65 in women), elevated Lp(a) is one of the most common identifiable genetic causes, often present in the context of otherwise unremarkable standard lipid panels.
- Treatment threshold and monitoring: because Lp(a) is genetically determined, it typically only needs to be measured once in a lifetime. A single result above 125 nmol/L identifies a patient who requires lifelong intensified cardiovascular risk management, even if Lp(a) cannot yet be directly lowered with available therapies.
3. Standard Lab Reference Range and Risk Stratification
| Lp(a) Level (nmol/L) | Risk Category | Clinical Significance |
|---|---|---|
| Below 30 nmol/L | Low risk | Minimal Lp(a)-attributable cardiovascular risk |
| 30 to 75 nmol/L | Borderline risk | Moderate Lp(a) burden; requires context of other risk factors |
| 75 to 125 nmol/L | High risk | Significant independent cardiovascular risk factor |
| Above 125 nmol/L | Very high risk | Risk equivalent to familial hypercholesterolemia; intensified management required |
Lp(a) reporting units vary by laboratory. Some labs report in mg/dL (older mass units); most guidelines now prefer nmol/L (particle concentration). The conversion is approximately 1 nmol/L equals 0.4 mg/dL, but this is imprecise because particle size varies. Always note the units when comparing results. A result of 50 mg/dL is approximately 125 nmol/L in the very high risk category.
4. What Lp(a) Elevation Does to Cardiovascular Risk
Atherogenic Mechanisms
- Contains an LDL-like core that delivers cholesterol to arterial walls like LDL does, contributing to plaque formation
- Carries a disproportionate fraction of oxidized phospholipids (OxPL) in the circulation, which are potent drivers of vascular inflammation and foam cell formation
- OxPL on Lp(a) activates endothelial cells, macrophages, and smooth muscle cells, promoting inflammatory plaque progression
- Associated with calcific aortic valve stenosis through OxPL-mediated valve inflammation and calcification
- Promotes coronary and peripheral atherosclerosis with accelerated plaque progression
Prothrombotic Mechanisms
- Apo(a) structurally mimics plasminogen and competitively inhibits its binding to fibrin clots
- Reduces tissue plasminogen activator (tPA)-mediated fibrinolysis, impairing clot dissolution
- Promotes thrombus formation at sites of endothelial injury or existing plaque
- Combined atherogenic plus prothrombotic mechanism explains why Lp(a) is particularly associated with myocardial infarction and ischemic stroke
- Venous thromboembolism (DVT and PE) risk is also elevated with high Lp(a), though less dramatically than arterial events
5. Who Should Be Tested for Lp(a)?
The European Atherosclerosis Society and most major cardiovascular guidelines recommend at least one lifetime Lp(a) measurement for all adults. Priority groups include:
- Personal history of premature cardiovascular disease (MI before 55 in men, before 65 in women) with otherwise unexplained risk
- Family history of premature cardiovascular disease or elevated Lp(a) in a first-degree relative
- Familial hypercholesterolemia (FH): elevated Lp(a) is present in 30 to 40% of FH patients and multiplicatively amplifies their already elevated risk
- Recurrent cardiovascular events despite optimal LDL lowering therapy
- Aortic valve stenosis without typical risk factors
- Intermediate cardiovascular risk on standard calculators (10-year risk 7.5 to 20%): Lp(a) often reclassifies risk upward and changes treatment decision
- Any patient in whom knowing Lp(a) would change clinical management
6. Current and Emerging Options for Elevated Lp(a)
Partially Effective Current Agents
- PCSK9 inhibitors (evolocumab, alirocumab): the most effective currently available agents for Lp(a) lowering, reducing serum Lp(a) by 20 to 30% as an off-target effect alongside their primary LDL-lowering role; already recommended for high cardiovascular risk patients with elevated LDL, and the Lp(a)-lowering effect is an additional benefit
- Niacin (nicotinic acid, 1 to 2g daily): reduces Lp(a) by 20 to 30% in multiple studies; however, the AIM-HIGH and HPS2-THRIVE trials failed to demonstrate cardiovascular event reduction despite effective niacin-mediated Lp(a) and lipid changes, limiting enthusiasm for niacin specifically for this indication; significant tolerability issues (flushing, glucose elevation)
- Aspirin: does not lower Lp(a) but partially addresses the prothrombotic mechanism; used in many high-risk Lp(a) patients for its antiplatelet effects
Emerging Therapies (Pipeline)
- Pelacarsen (TQJ230): antisense oligonucleotide targeting LPA mRNA in the liver; OCEAN(a)-OUTCOMES Phase 3 trial; reduces Lp(a) by 70 to 80%; results expected 2025
- Olpasiran (AMG 890): small interfering RNA (siRNA) targeting LPA gene expression; Phase 2 OCEAN(a) trial demonstrated 70 to 98% Lp(a) reduction; Phase 3 trial enrolling
- Zerlasiran (SLN360): siRNA therapy; 60 to 90% Lp(a) reduction in Phase 1; Phase 2 data expected
- Muvalaplin: small molecule oral LPA inhibitor; novel mechanism; early clinical trial data showing 65 to 85% Lp(a) reduction
- These RNA-based therapies represent the first generation of Lp(a)-specific treatments and, if Phase 3 outcomes trials confirm cardiovascular event reduction, will transform management of elevated Lp(a)
Risk Management Strategy
- Aggressively lower all other modifiable cardiovascular risk factors: Lp(a) risk is multiplicative with LDL, hs-CRP, blood pressure, and metabolic syndrome; optimizing everything else substantially reduces overall risk even when Lp(a) cannot yet be lowered
- Achieve very aggressive LDL and ApoB targets: when Lp(a) is elevated, aim for ApoB below 60 mg/dL and LDL below 70 mg/dL; PCSK9 inhibitors serve double duty by lowering both LDL and Lp(a)
- hs-CRP reduction: lower the inflammatory milieu in which Lp(a) operates through diet, omega-3s, and lifestyle; reduces the inflammatory amplification of Lp(a)-mediated plaque progression
- Aspirin (low-dose) consideration: partially addresses the prothrombotic arm of Lp(a) risk; decision requires individual risk-benefit assessment with prescribing physician
- Lipoprotein apheresis: LDL apheresis also removes Lp(a) by 60 to 75% per session; used in severe refractory cases; approved for Lp(a) hyperlipoproteinemia in some European countries
- Lifestyle: while diet and exercise do not substantially lower Lp(a), they reduce total cardiovascular burden; Mediterranean diet, omega-3s, smoking cessation, and blood pressure control are all still indicated
7. Related Lab Tests
ApoBTotal Atherogenic Particle Burden
→
hs-CRPInflammatory Context for Lp(a) Risk
→
HomocysteineCardiovascular Risk Co-marker
→
TG/HDL RatioMetabolic Cardiovascular Risk Context
→
Omega-3 IndexAnti-Inflammatory Companion Assessment
→
AA/EPA RatioInflammatory Balance Marker
→
8. When Testing Is Recommended
- Every adult should have Lp(a) measured at least once; major guidelines recommend universal screening
- Lp(a) is genetically stable; a single measurement is sufficient for most patients (does not need annual retesting)
- Premature cardiovascular disease or unexplained cardiovascular events in otherwise low-risk individuals
- Family history of premature cardiovascular disease or known elevated Lp(a) in a first-degree relative
- Established familial hypercholesterolemia: Lp(a) elevates risk multiplicatively and influences treatment intensity
- Intermediate cardiovascular risk on standard calculators: Lp(a) frequently reclassifies risk upward and changes treatment decisions
- Recurrent cardiovascular events despite optimal LDL treatment: elevated Lp(a) may explain therapeutic failure
- Aortic valve stenosis evaluation: Lp(a) is strongly associated with calcific aortic valve disease
9. Clinical Perspective
Clinical Perspective
Lp(a) is the test that changes the entire clinical conversation, because it is the only cardiovascular risk factor I routinely find that is fully genetic, cannot be fixed with lifestyle changes, and requires a fundamentally different long-term management strategy than anything else I measure. When I find an Lp(a) of 180 nmol/L in a 44-year-old who exercises, eats well, and has normal LDL, I now know that their standard risk calculator is lying to them. Their true lifetime cardiovascular risk is far higher than it appears, and the management response is not to tell them to keep doing what they are doing. It is to drive their ApoB aggressively below 60, to reduce every other modifiable risk factor to its lowest possible level, to track the progression of aortic valve calcification with echocardiography, and to get them to understand the importance of the RNA-based therapies that are coming. I also test first-degree family members. This is a family diagnosis, not just an individual one, and the earlier it is found, the more time there is to manage the compounding risk it creates.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
10. Frequently Asked Questions
What is lipoprotein(a)?
Lipoprotein(a) is a genetically determined lipoprotein particle consisting of an LDL-like core with an additional protein (apolipoprotein(a)) covalently attached. Serum Lp(a) levels are 80 to 90% genetically determined and are largely unresponsive to diet, exercise, or most lipid-lowering medications. Lp(a) is both atherogenic (like LDL) and prothrombotic (inhibits fibrinolysis), making it a uniquely dangerous cardiovascular risk factor.
What Lp(a) level is considered dangerous?
Risk rises progressively. The European Atherosclerosis Society defines very high risk as above 125 nmol/L, equivalent to familial hypercholesterolemia in cardiovascular risk. Lp(a) above 75 nmol/L carries significantly elevated risk. Even 30 to 75 nmol/L adds meaningful risk in the context of other cardiovascular risk factors. Lp(a) risk is multiplicative: elevated Lp(a) combined with elevated ApoB, hypertension, or metabolic syndrome dramatically amplifies overall cardiovascular risk.
How do you lower Lp(a)?
Lp(a) is largely genetically determined and does not respond meaningfully to standard lifestyle changes. PCSK9 inhibitors reduce Lp(a) by 20 to 30% as an off-target effect. Niacin reduces Lp(a) by 20 to 30% but has not demonstrated cardiovascular event reduction. RNA-based therapies in late-stage clinical trials (pelacarsen, olpasiran, zerlasiran) reduce Lp(a) by 70 to 98% and represent the first generation of Lp(a)-specific treatments. Until these are available, the strategy is aggressive management of all other modifiable cardiovascular risk factors.
Why have most people never had Lp(a) tested?
Lp(a) is not included in standard lipid panels ordered by most primary care providers. Despite guidelines from the American College of Cardiology, European Society of Cardiology, and National Lipid Association recommending at least one lifetime Lp(a) measurement for all adults, this has not yet become universal clinical practice. Approximately 20% of the population has Lp(a) above 125 nmol/L and does not know it.
How often should Lp(a) be tested?
Because Lp(a) is genetically determined and remains largely constant throughout adult life, it typically only needs to be measured once. Repeat testing is indicated if significant changes in clinical status occur, if initiating or discontinuing PCSK9 inhibitors (which affect Lp(a) by 20 to 30%), or to confirm an unexpectedly high or low initial result.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Approximately 1 in 5 people has an Lp(a) that significantly elevates their lifetime cardiovascular risk. Most have never been tested.
Lp(a) is the most important cardiovascular risk factor most patients have never heard of. Schedule a consultation for a complete cardiovascular risk assessment including Lp(a).
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.